search
Back to results

Magnetic Randomized Trial in Elderly Depressed (MrTED)

Primary Purpose

Major Depressive Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Transcranial magnetic stimulation
Sponsored by
University of Sao Paulo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring major depressive disorder, geriatric depression, repetitive transcranial magnetic stimulation (rTMS), theta-burst stimulation (TBS), elderly

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Major Depressive Disorder;
  • Patients older than 60 years
  • Hamilton equal or higher than 17

Exclusion Criteria:

  • Other mental disorders (alcohol or drug addiction, psychotic disorders, dementia, bipolar disorder);
  • Presence of serious neurological or clinical diseases;
  • Resence of severe suicidal ideation and CIRS (Cumulative Illness Rating Scale) score> 7, characterizing a set of clinical morbidities that could impair adherence to the research protocol, bipolar disorder and/or presence of manic symptoms (hypo) demonstrated with more than 8 points in the Young Mania Rating Scale.
  • Metal implants;
  • Epilepsy or electronics in the cephalic segment;

Sites / Locations

  • University of Sao PauloRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Active Stimulation

Sham Stimulation

Arm Description

Active Comparator: Active stimulation with pulses emitted according to intervention description

Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.

Outcomes

Primary Outcome Measures

Changes in Hamilton Rating Scale for Depression, 17 items (HDRS-17)
Continuous measure (score changes).

Secondary Outcome Measures

Change in HDRS-17
Continuous measure (score changes).
Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Continuous measure (score changes).
Change in Global Clinical Impression Scale (CGI)
Continuous measure (score changes).
Change in Cumulative Illness Rating Scale (CIRS)
Continuous measure (score changes).
Change in Geriatric Depression Scale (GDS)
Continuous measure (score changes).
Change in Positive and Negative Affect Scale (PANAS)
Continuous measure (score changes).
Change in serum BDNF concentrations
Continuous measure (score changes).
Response HDRS 17
Response (≥50% improvement from week 0 to 12)
Remission of HDRS 17
Remission (HDRS-17 ≤ 8)
Young Manic Rating Scale (YMRS)
Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events
Serious adverse events
Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events

Full Information

First Posted
January 20, 2021
Last Updated
November 9, 2021
Sponsor
University of Sao Paulo
Collaborators
Brain & Behavior Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04842929
Brief Title
Magnetic Randomized Trial in Elderly Depressed
Acronym
MrTED
Official Title
Treatment of Depression in the Elderly With Repetitive Transcranial Magnetic Stimulation (rTMS) Using Theta-burst Stimulation (TBS): Randomized, Double-blind, Sham-controlled, Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 16, 2019 (Actual)
Primary Completion Date
September 20, 2022 (Anticipated)
Study Completion Date
December 20, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo
Collaborators
Brain & Behavior Research Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness, adverse effects and drug interactions, especially in the elderly population. In this context, the investigators investigate a non-pharmacological treatment known as recurrent transcranial magnetic stimulation (rTMS) with the theta-burst stimulation (TBS) method for the treatment of geriatric depression. This treatment modality has almost no adverse effects and avoids the risk associated with polypharmacy, providing an interesting alternative to antidepressant treatments. Our aim is to evaluate TBS efficacy in the treatment of geriatric depression in a randomized, double-blind, placebo-controlled clinical trial.
Detailed Description
Recurrent transcranial magnetic stimulation (rTMS) is a consolidated procedure for the treatment of depression, with several meta-analyzes demonstrating its efficacy. The theta-burst stimulation (TBS) method is a modification of the usual rTMS protocol. As a new protocol, there are still few studies evaluating its efficacy in treatment of major depression, although a recently published meta-analysis has pointed to benefits of this therapeutic modality. To date, there are no studies published with this method for the treatment of geriatric depression. This study will be a randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of theta-burst rTMS in the treatment of major depressive disorder in the elderly, randomizing 108 subjects to the experimental (TBS) and comparative (sham) groups. The coil will be positioned in the dorsolateral prefrontal cortex, with intermittent TBS (iTBS, stimulatory) mode on the left and continuous TBS (cTBS, inhibitory) on the right. Stimulation protocol consists of 1800 pulses on each brain hemisphere, totaling a ten minutes session. There will be 20 consecutive sessions, one a day, except on weekends and holidays. The cycle of continuous intervention will last approximately four weeks, after which applications with the same technique will be performed at the end of weeks 6, 8 and 12. Clinical outcome measures will be obtained on eight occasions: treatment baseline, and after 1, 2, 4, 6, 8 and 12 weeks of onset. The main clinical outcome will be measured using the Hamilton Depression Scale (HDRS), comparing baseline scores with those obtained after 6 weeks of treatment. As secondary endpoints, we will use the Global Clinical Impression Scale (CGI), the CIRS (Cumulative Illness Rating Scale), the Geriatric Depression Scale (GDS), the intermediate scores obtained on the HDRS scale, the Positive and Negative Affect Scale (PANAS), the Montgomery-Asberg Depression Rating Scale (MADRS), and variations in serum BDNF concentrations; all these evaluation tools have validated versions in Portuguese. As tolerability and safety parameters, the incidence of adverse events and the occurrence of manic/hypomanic symptoms will be evaluated by the Young Mania Scale (YMRS). TBS stimulation will be evaluated in terms of safety, tolerability and effectiveness for the treatment of major depression in the elderly, possibly becoming another therapeutic option useful for patients with poor response or contraindications to the use of antidepressants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
major depressive disorder, geriatric depression, repetitive transcranial magnetic stimulation (rTMS), theta-burst stimulation (TBS), elderly

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Stimulation
Arm Type
Active Comparator
Arm Description
Active Comparator: Active stimulation with pulses emitted according to intervention description
Arm Title
Sham Stimulation
Arm Type
Sham Comparator
Arm Description
Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.
Intervention Type
Device
Intervention Name(s)
Transcranial magnetic stimulation
Intervention Description
The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
Primary Outcome Measure Information:
Title
Changes in Hamilton Rating Scale for Depression, 17 items (HDRS-17)
Description
Continuous measure (score changes).
Time Frame
Weeks 0 and 6
Secondary Outcome Measure Information:
Title
Change in HDRS-17
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in Global Clinical Impression Scale (CGI)
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in Cumulative Illness Rating Scale (CIRS)
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in Geriatric Depression Scale (GDS)
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in Positive and Negative Affect Scale (PANAS)
Description
Continuous measure (score changes).
Time Frame
Weeks 1, 2, 4, 6, 8, 12
Title
Change in serum BDNF concentrations
Description
Continuous measure (score changes).
Time Frame
Weeks 0 and 6
Title
Response HDRS 17
Description
Response (≥50% improvement from week 0 to 12)
Time Frame
Week 12
Title
Remission of HDRS 17
Description
Remission (HDRS-17 ≤ 8)
Time Frame
Week 12
Title
Young Manic Rating Scale (YMRS)
Description
Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events
Time Frame
Weeks 0, 1, 2, 4, 6, 8, 12
Title
Serious adverse events
Description
Serious adverse events include treatment-emergent hypomania/mania (YMRS>8), suicide, psychiatric hospitalization and others life-threatening or incapacitant events
Time Frame
Up to week 12
Other Pre-specified Outcome Measures:
Title
Conditioned pain modulation
Description
Temperature of the thermode reported as painful
Time Frame
Week 0 and 4
Title
Actigraphy
Description
Continuous measure (score changes).
Time Frame
1 week before treatment up to 4 weeks after finishing study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Major Depressive Disorder; Patients older than 60 years Hamilton equal or higher than 17 Exclusion Criteria: Other mental disorders (alcohol or drug addiction, psychotic disorders, dementia, bipolar disorder); Presence of serious neurological or clinical diseases; Resence of severe suicidal ideation and CIRS (Cumulative Illness Rating Scale) score> 7, characterizing a set of clinical morbidities that could impair adherence to the research protocol, bipolar disorder and/or presence of manic symptoms (hypo) demonstrated with more than 8 points in the Young Mania Rating Scale. Metal implants; Epilepsy or electronics in the cephalic segment;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Leandro Valiengo
Phone
(11) 2661-8159
Email
pesquisa.neuropsiquiatria@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leandro Valiengo
Organizational Affiliation
University of São Paulo
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Sao Paulo
City
Sao Paulo
State/Province
SP
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leandro Valiengo, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
36118977
Citation
Valiengo L, Pinto BS, Marinho KAP, Santos LA, Tort LC, Benatti RG, Teixeira BB, Miranda CS, Cardeal HB, Suen PJC, Loureiro JC, Vaughan RAR, Dini Mattar RAMPF, Lessa M, Oliveira PS, Silva VA, Gattaz WF, Brunoni AR, Forlenza OV. Treatment of depression in the elderly with repetitive transcranial magnetic stimulation using theta-burst stimulation: Study protocol for a randomized, double-blind, controlled trial. Front Hum Neurosci. 2022 Aug 31;16:941981. doi: 10.3389/fnhum.2022.941981. eCollection 2022.
Results Reference
derived

Learn more about this trial

Magnetic Randomized Trial in Elderly Depressed

We'll reach out to this number within 24 hrs